
Bristol-Myers Squibb Company is a drug manufacturers-general business based in the US. Bristol-Myers Squibb Company shares (BMY) are listed on the NYSE and all prices are listed in US Dollars. Bristol-Myers Squibb Company employs 32,200 staff and has a trailing 12-month revenue of around $46.7 billion.
How to buy Bristol-Myers Squibb Company stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – BMY. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
- BMY shares summary
- Compare share dealing platforms
- Is BMY stock a buy or sell?
- Stock performance over time
- Is BMY suitable for ethical investing?
- Are BMY shares over-valued?
- Bristol-Myers Squibb Company's financials
- How volatile are BMY shares?
- Does Bristol-Myers Squibb Company pay a dividend?
- Have BMY shares ever split?
- Other common questions
Bristol-Myers Squibb Company stock price (NYSE: BMY)
Use our graph to track the performance of BMY stocks over time.Bristol-Myers Squibb Company shares at a glance
Latest market close | $73.17 |
---|---|
52-week range | $60.97 - $80.80 |
50-day moving average | $75.55 |
200-day moving average | $74.52 |
Wall St. target price | $82.19 |
PE ratio | 23.5273 |
Dividend yield | $2.16 (3.15%) |
Earnings per share (TTM) | $3.11 |
Buy Bristol-Myers Squibb Company stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Bristol-Myers Squibb Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bristol-Myers Squibb Company price performance over time
Historical closes compared with the close of $73.17 from 2023-01-25
1 week (2023-01-19) | -0.79% |
---|---|
1 month (2022-12-23) | 0.38% |
3 months (2022-10-26) | -1.72% |
6 months (2022-07-26) | -0.62% |
1 year (2022-01-26) | 17.56% |
---|---|
2 years (2021-01-26) | 13.55% |
3 years (2020-01-24) | 14.04% |
5 years (2018-01-26) | 13.88% |
Is Bristol-Myers Squibb Company stock undervalued or overvalued?
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's P/E ratio
Bristol-Myers Squibb Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Bristol-Myers Squibb Company shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Bristol-Myers Squibb Company's PEG ratio
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4369. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.7 billion.
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.
Bristol-Myers Squibb Company financials
Revenue TTM | $46.7 billion |
---|---|
Operating margin TTM | 21.95% |
Gross profit TTM | $37 billion |
Return on assets TTM | 6.13% |
Return on equity TTM | 19.12% |
Profit margin | 14.29% |
Book value | $15.38 |
Market capitalisation | $155.6 billion |
TTM: trailing 12 months
Bristol-Myers Squibb Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bristol-Myers Squibb Company's total ESG risk score
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bristol-Myers Squibb Company's environmental score
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's social score
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol-Myers Squibb Company's governance score
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.
Total ESG score | 29.16 |
---|---|
Total ESG percentile | 52.58 |
Environmental score | 3.83 |
Environmental score percentile | 4 |
Social score | 18.82 |
Social score percentile | 4 |
Governance score | 14.02 |
Governance score percentile | 4 |
Level of controversy | 2 |
Bristol-Myers Squibb Company share dividends
Dividend payout ratio: 15.8% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 15.8% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.15% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 3.15% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.16 per share.
While Bristol-Myers Squibb Company's payout ratio might seem low, this can signify that Bristol-Myers Squibb Company is investing more in its future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 31 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 4 January 2023 (the "ex-dividend date").
Have Bristol-Myers Squibb Company's shares ever split?
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
Bristol-Myers Squibb Company share price volatility
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as $60.9691 up to $80.8008. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.4255. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
Bristol-Myers Squibb Company overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company.
Bristol-Myers Squibb Company in the news
Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
Frequently asked questions
What percentage of Bristol-Myers Squibb Company is owned by insiders or institutions?Currently 0.067% of Bristol-Myers Squibb Company shares are held by insiders and 79.398% by institutions. How many people work for Bristol-Myers Squibb Company?
Latest data suggests 32,200 work at Bristol-Myers Squibb Company. When does the fiscal year end for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company's fiscal year ends in December. Where is Bristol-Myers Squibb Company based?
Bristol-Myers Squibb Company's address is: 430 East 29th Street, New York, NY, United States, 10016 What is Bristol-Myers Squibb Company's ISIN number?
Bristol-Myers Squibb Company's international securities identification number is: US1101221083 What is Bristol-Myers Squibb Company's CUSIP number?
Bristol-Myers Squibb Company's Committee on Uniform Securities Identification Procedures number is: 110122108
More guides on Finder
-
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert